Evidence map›Paper›PMID 39491045›Full record

ArticleCancer science2025

Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers.

Yitong Tian, Changxian Li, Ke Jin, Ling Ma, Jiaguang Zhang, Xinyi Zhang, Wei You, Haoyang Shen, Yuting Ding, Hao Qian and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yitong TianDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0009-0005-1650-8065
Changxian LiHepatobiliary Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Ke JinDepartment of Medical Oncology, Liyang People's Hospital, Liyang, China.
Ling MaDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Jiaguang ZhangDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Xinyi ZhangDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Wei YouHepatobiliary Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Haoyang ShenDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Yuting DingDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Hao QianDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Xiangcheng LiHepatobiliary Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Xiaofeng ChenDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0002-0754-951X

Funding

Beijing Xisike Clinical Oncology Research Foundation Y-HR2019-0367Science and Technology Development Fund project of Pukou Branch of Jiangsu Provincial People's Hospital in 2021 KJ2021-1
6 · The paper itself

Abstract

The efficacy of combined chemotherapy and immunotherapy has previously been demonstrated in patients with biliary tract cancer. The aim of this study was to assess the efficacy and safety of camrelizumab in combination with gemcitabine and apatinib as a first- or second-line treatment for advanced programmed death-ligand 1 (PD-L1)-positive biliary tract cancer. This prospective, single-arm, and exploratory clinical trial aimed at recruiting 20 PD-L1-positive patients (tumor proportion score ≥1% or combined positive score ≥1) who met the inclusion criteria. Camrelizumab (200 mg) was administered in combination with gemcitabine (800 mg/m

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBiliary Tract NeoplasmsDeoxycytidineGemcitabinePyridinesAdultAgedFemaleHumansMaleMiddle AgedProgression-Free SurvivalProspective StudiesAntibodies, Monoclonal, HumanizedapatinibB7-H1 AntigencamrelizumabCD274 protein, humanDeoxycytidineGemcitabinePyridinesadvanced biliary tract cancerapatinibcamrelizumabgemcitabinePD‐L1 positive

Identifiers

PMID39491045
PMCPMC11711057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.